This is a routine board refresh with no financial or operational implications. No trading action warranted. Monitor for any future strategic shifts that Boulud's diagnostics background might influence, but no near-term catalyst.
Price Chart
Executive Summary
STERIS filed an 8-K reporting the retirement of director Richard C. Breeden (not standing for reelection after 18 years) and the appointment of Pierre Boulud, CEO of bioMérieux, to the board. This is a routine board refresh with no material financial impact — no financial data, guidance, or operational changes were disclosed.
Key Facts
- Director Richard C. Breeden will not stand for reelection at the 2026 Annual General Meeting; his retirement is not due to any disagreement with the company.
- Board size increased from 9 to 10 members; Pierre Boulud appointed effective May 5, 2026.
- Pierre Boulud is CEO of bioMérieux (in vitro diagnostics) and previously held senior roles at Ipsen and Boston Consulting Group.
- Boulud will receive a prorated fee of $76,989 in career restricted stock units for the remainder of the board's 2025-26 term.
Financial Impact
No material financial impact. Director compensation of $76,989 in restricted stock units is immaterial for a $21B market cap company.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-212159 |
| Document: d27562dex991.htm | 0001193125-26-212159 |
| Document: 0001193125-26-212159-index-headers.html | 0001193125-26-212159 |
| Document: 0001193125-26-212159-index.html | 0001193125-26-212159 |
| Document: 0001193125-26-212159.txt | 0001193125-26-212159 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | Press Release | $230.34 $236.44 | ▲ +2.65% | ▼ −0.73% | $207.99 (−9.70%) |
Jun 15, 2026 15w ago | 144 | $206.51 $208.73 | ▲ +1.07% | ▲ +0.88% | $207.99 (+0.72%) |
Jun 11, 2026 16w ago | DEFA14A | $207.56 $216.00 | ▲ +4.07% | ▲ +2.29% | $207.99 (+0.21%) |
Jun 8, 2026 16w ago | Insider Cluster | $212.88 $215.39 | ▲ +1.18% | ▼ −0.27% | $207.99 (−2.30%) |
Jun 5, 2026 16w ago | 144 | $210.03 $213.28 | ▲ +1.55% | ▼ −0.08% | $207.99 (−0.97%) |
Jun 4, 2026 17w ago | 144 | $212.35 $213.28 | ▲ +0.44% | ▼ −1.42% | $207.99 (−2.05%) |
May 11, 2026 20w ago | 8-K | $210.23 $208.10 | ▲ +1.01% | ▼ −0.71% | $207.99 (+1.07%) |
May 11, 2026 20w ago | Press Release | $210.23 $208.10 | ▼ −1.01% | ▲ +0.71% | $207.99 (−1.07%) |
May 7, 2026 21w ago | 8-K | $207.24 $212.35 | ▲ +2.47% | ▲ +2.44% | $207.99 (+0.36%) |
Apr 21, 2026 23w ago | Press Release | $222.61 $214.42 | ▼ −3.68% | ▼ −6.84% | $207.99 (−6.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access